Pharma vs FDA Actions
Side-by-side coverage analysis for Pharma and FDA Actions.
This comparison applies the same classification pipeline used across every story on this site, which scores each linked entity at a minimum 35 percent relevance threshold before it is surfaced. According to our editorial methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
Pharma
Drug pricing, commercialization, pharma industry news
- Stories
- 523
- Avg Impact
- 5.9/10
- Dominant Tone
- Neutral
- Latest
- 14m ago
FDA Actions
Approvals, rejections, priority reviews
- Stories
- 73
- Avg Impact
- 6.6/10
- Dominant Tone
- Positive
- Latest
- 2d ago
Recent Headlines
Pharma
- Rabies Vaccine Use Up 33%, HRIG Up 76% in 2026
- Anthropic's 9-Month Misuse Audit Flags Bioweapons Research Threats
- Anthropic's 3rd threat report details blocked AI bioweapons research
- Protagonist's $300M Buyback: Rare Cash Return After 2 FDA Wins
- 18 Lab Distributors Add ACT Ecolabel Data Ahead of EU Green Claims Rules
- Bharat Health Expo 2026: India Names Biosimilars Next Pharma Frontier
- 2026 Expo: India Must Lead in New Molecules and Biotech, Says Goyal
- Pharma's drug-price deals: $0 enforcement, $0 penalties
- KAISHA Pharma Launches With 45M Push Into Biologics-Grade Packaging
- Boston Scientific Cyberattack Threatens Q3 Revenue by 600-700 bps
FDA Actions
- 3 in 5 abortions use mifepristone as 5th Circuit weighs limits
- FDA Drug Chief to Oversee 3 Psychedelic Candidates: Psilocybin, MDMA, LSD
- FDA Names 4 Center Directors as Psychedelics Reviews Take Shape
- Mifepristone in 60% of U.S. abortions faces FDA rule fight in 5th Circuit
- Endometriosis tests advance abroad while U.S. lags for 1 in 10 women
- Rasonque Approved: KRAS Inhibitor Doubles Survival to 13.2 Months
- ICP DAS-BMP TPU with 20-40% Barium Sulfate Targets Implantable Devices
- Druckenmiller's Q2 RYTM Bet Targets 2 FDA Nods in Rare Obesity
- Zeon's FDA FSMA + NSF 21 CFR Part 111 cGMP Boost India CDMO Credibility
- Opdivo's 1/12th Dose Shows Efficacy in Indian Study, Sparking FDA Label Debate